Minocycline News and Research

RSS

Minor mutations can lead to big improvements in antibiotic resistance

Rice University scientists have found that mutations of small effect can turn out to be game changers in the bacterial fight against antibiotic drugs.

10 Jan 2013

JNS announces publication of NACTN/AOSNA Focus Issue on Spinal Cord Injury

The Journal of Neurosurgery (JNS) Publishing Group is proud to announce publication of the NACTN/AOSNA Focus Issue on Spinal Cord Injury, a supplement to the September issue of the Journal of Neurosurgery: Spine, which is sponsored by AOSpine North America available in print and online.

3 Sep 2012

TYRX enrolls 1000th patient in CITADEL/CENTURION AIGISRx Antibacterial Envelope studies

TYRX, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with cardiovascular implantable electronic devices (CIEDs), announced today that the 1000th patient has been enrolled into the CITADEL & CENTURION clinical studies evaluating the company's AIGISRx Antibacterial Envelope.

2 Apr 2012

Cook Medical, Cardinal Health partner to distribute CVC procedural kits in North America

Cardinal Health and Cook Medical today announced a two-year, exclusive agreement for the North American distribution of Cook Medical central venous catheter (CVC) sets with Cardinal Health Presource customizable procedural kits ─ providing clinicians with advanced technology the flexibility of customization for their vascular access needs.

31 Jan 2012

Minocycline, EDTA may combat catheter-related bacterial infections in dialysis patients

Antibiotics can help ward off serious bacterial infections in kidney disease patients who use tubes called catheters for their dialysis treatments. But if antibiotics are used too often, "super bugs" may crop up that are resistant to the drugs.

19 Aug 2011

Dermatologist discusses common skin conditions that affect people of color at AAD 2011 meeting

The U.S. Census Bureau predicts that by the year 2050, more than half the U.S. population will have skin of color. Recognizing this trend, dermatologists are educating the public about the different ways that common skin conditions appear in various skin tones.

5 Aug 2011

Creative approach can tackle bacterial infections in patients with cystic fibrosis

An over-the-counter drug used to treat diarrhea combined with minocycline, an antibiotic used to treat bacterial infections, could one day change the lives of those living with cystic fibrosis.

25 Apr 2011

Anacor, Medicis collaborate to discover and develop boron-based treatment for acne

Anacor Pharmaceuticals, Inc. and Medicis Pharmaceutical Corporation today announced that the two companies have entered into a research and development agreement to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne.

11 Feb 2011

Water Street Healthcare announces acquisition of OraPharma from Johnson & Johnson

Water Street Healthcare Partners announced today that it has acquired OraPharma, Inc. from Johnson & Johnson. Water Street, a strategic private equity firm focused exclusively on health care, plans to build OraPharma into a leading specialty pharmaceutical company focused on dental and oral health care.

6 Jan 2011

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.

17 Nov 2010

CIED implantation with AIGISRx Antibacterial Envelope reduces overall infection rate

Patients undergoing CIED (Cardiac Implantable Electronic Device) implantation with TYRX, Inc.'s FDA-cleared AIGISRx Antibacterial Envelope enjoyed a 99.5% rate of successful implantation with an overall infection rate of 0.48% in the first 1.9 months following the procedure, as reported in newly published results of TYRX's COMMAND Clinical Study.

20 Oct 2010

Cook Medical expands Spectrum Turbo-Ject line of antibiotic impregnated PICCs for CRBSIs

Responding to increased demand for technology to help prevent potentially fatal catheter-related bloodstream infections (CRBSIs), Cook Medical has expanded its Spectrum Turbo-Ject line of antibiotic impregnated peripherally inserted central venous catheters (PICCs) to treat a wider range of patient needs. For the first time, the clinical benefits of minocycline and rifampin-impregnated PICCs, a critical component in eliminating 250,000 potentially fatal CRBSIs in the U.S. annually, are now available in 3 French single and 6 French triple lumen sizes.

21 Sep 2010

Researchers suggest potentially valuable role for minocycline plus N-acetylcysteine to treat TBI

Traumatic brain injury is a serious public health problem in the United States. Recent data show that approximately 1.7 million people sustain a traumatic brain injury annually. While the majority of TBIs are concussions or other mild forms, traumatic brain injuries contribute to a substantial number of deaths and cases of permanent disability.

18 Sep 2010

Minocycline plus N-acetylcysteine may help treat TBI

Traumatic brain injury (TBI) is a serious public health problem in the United States. Recent data show that approximately 1.7 million people sustain a traumatic brain injury annually. While the majority of TBIs are concussions or other mild forms, traumatic brain injuries contribute to a substantial number of deaths and cases of permanent disability.

18 Sep 2010

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

An antibiotic appears to be a safe treatment for stroke and a good companion therapy for tPA, the clot buster that is currently the only FDA-approved drug therapy, researchers report.

13 Sep 2010

Researchers find minocycline antibiotics effective for fragile X syndrome

One of the antibiotics most commonly prescribed to treat adolescent acne can increase attention spans and communication and decrease anxiety in patients with fragile X syndrome, the most common inherited cause of mental impairment, according to a new survey study that is the first published on parents' reports of their children's responses to treatment with the medication.

9 Sep 2010

USPTO awards Medicis new patent for SOLODYN Extended Release Tablets

Medicis today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,790,705 related to the use of SOLODYN® (minocycline HCI, USP) Extended Release Tablets. The new patent, entitled "Minocycline Oral Dosage Forms for the Treatment of Acne," relates to the use of dosage forms of SOLODYN which provide approximately 1 mg/kg dosing based on the body weight of the person, and expires in 2027.

8 Sep 2010

FDA approves additional strengths of SOLODYN for inflammatory lesions treatment

Medicis today announced that the U.S. Food and Drug Administration (FDA) has approved additional strengths of SOLODYN (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

30 Aug 2010

FDA approves Mylan's ANDA for generic Solodyn ER tablets for acne treatment

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited received final approval on July 20 from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Minocycline Hydrochloride Extended Release Tablets (Minocycline ER), 45 mg, 90 mg and 135 mg, the generic version of Solodyn® ER, a treatment for acne, sold by Medicis Pharmaceuticals Corporation (Medicis). Mylan Pharmaceuticals Inc. commenced immediate shipment of the product after approval.

23 Jul 2010

TYRX successfully implants AIGISRx device in 10,000 patients in the U.S.

TYRX, Inc. announced today that it has successfully implanted its AIGISRx device in 10,000 patients in the United States. The AIGISRx device is an antibacterial mesh technology that securely holds a pacemaker or implantable cardioverter defibrillator in place to create a stable environment, while delivering antimicrobial agents, rifampin and minocycline. These antimicrobial agents have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.

15 Jun 2010